Nebenwirkungen · Riluzole Zentiva
Riluzole Zentiva 50 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 5
HOS-218999 · Präparat HOS-216293
Hepato-biliary disorders Increased alanine aminotransferase usually appeared within 3 months after the start of therapy with riluzole; they were usually transient and levels returned to below twice the ULN after 2 to 6 months while treatment was continued. These increases could be associated with jaundice. In patients (n=20) from clinical studies with increases in ALT to more than 5 times the ULN, treatment was discontinued and the levels returned to less than 2 times the ULN within 2 to 4 months in most cases (see section 4.4) Study data indicate that Asian patients may be more susceptible to liver function test abnormalities - 3.2% (194/5995) of Asian patients and 1.8% (100/5641) of Caucasian patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-15T14:00:00Z · SHA-256 1ebce6a1ea8cfcd37b0a250dfca17176f3f6881ab45dbb76ba8eb11901c00ea3 · Passage eb718abb2f6a229a1d9ae342f2cb18e847b0959de06422bb3324822d6839869a · Zeichen 2350–3063 im Abschnitt